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KRASmutation, which occurs in95% of pancreatic
ductal adenocarcinoma (PDA), has been shown to
program tumor metabolism. MCT4 is highly upre-
gulated in a subset of PDA with a glycolytic gene
expression program and poor survival. Models with
high levels of MCT4 preferentially employ glycolytic
metabolism. Selectively in such ‘‘addicted’’ models,
MCT4 attenuation compromised glycolytic flux with
compensatory induction of oxidative phosphoryla-
tion and scavenging of metabolites by macropinocy-
tosis and autophagy. In spite of these adaptations,
MCT4 depletion induced cell death characterized
by elevated reactive oxygen species and metabolic
crisis. Cell death induced by MCT4-depletion was
augmented by inhibition of compensatory pathways.
In xenograft models, MCT4 had a significant impact
on tumor metabolism and was required for rapid
tumor growth. Together, these findings illustrate
the metabolic diversity of PDA described by MCT4,
delineate pathways through which this lactate trans-
porter supports cancer growth, and demonstrate
that PDA can be rationally targeted based on meta-
bolic addictions.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) has a particularly poor
prognosis, and even with new targeted therapies and chemo-
therapy, the 5-year survival rate of pancreatic cancer is 6%
(Bardeesy and DePinho, 2002; Hezel et al., 2006; Wolfgang
et al., 2013; Wood and Hruban, 2012). Due to this recalcitrance
to therapy, it is important to understand the biology of PDA
and identify putative therapeutic targets beyond the currentCell Refocus on chemotherapy or therapies directed at deregulated
oncogenic pathways (Almhanna and Philip, 2011). One of the
key challenges in the treatment of pancreatic cancer is the lack
of defined subtypes of disease to which therapy should be
directed (Tempero et al., 2013), and therefore, unlike other can-
cers, PDA is treated largely as a single disease type.
One of the emerging and provocative therapeutic approaches
is to target specific metabolic dependencies of cancer (Cheong
et al., 2012; Deberardinis et al., 2008; Le et al., 2012; White,
2013). PDA exhibits the presence of abundant desmoplastic
stroma, which accounts for the majority of tumor volume (Chu
et al., 2007; Erkan et al., 2012). Dense fibrotic stroma in connec-
tion with poor vascularization results in a hypoxic and acidic
microenvironment (Brahimi-Horn et al., 2011; Ide et al., 2007;
Neesse et al., 2011). This environment and the presence of acti-
vated KRAS are believed to promote a reprogramming of meta-
bolism within tumor cells to favor glycolysis. However, it is clear
that the metabolic features of disease are complex, and PDA is
known to utilize multiple independent processes and nutrients
for energy and to provide precursors of proteins, nucleic acids,
and membrane lipids (Le et al., 2012; Son et al., 2013). Addition-
ally, PDA has been described to exhibit high levels of autophagy
and macropinocytosis to ostensibly scavenge macromolecules
to fuel tumor cell proliferation and enable survival under stress
conditions (Commisso et al., 2013; Yang and Kimmelman,
2011; Yang et al., 2011). The complex flow of nutrient sources
into the tumor cells suggests that targeting common aspects
of the efflux of metabolic waste may represent a particularly
important feature of PDA (Parks et al., 2013).
Many cancer cells activate aerobic glycolysis and convert the
majority of glucose into lactate, even when oxygen is available
for oxidative phosphorylation (Halestrap and Price, 1999; Hale-
strap and Wilson, 2012). To survive the accumulation of lactate
and maintain an intracellular acid-base balance, cancer cells ac-
quire proton pumps, sodium-proton exchangers, bicarbonate
transporters, and monocarboxylate transporters (MCTs). MCTs
are transmembrane proteins that facilitate the transport of
short-chain carbohydrates such as pyruvate and lactate, withports 9, 2233–2249, December 24, 2014 ª2014 The Authors 2233
p value:   3.02e-8 1. Bladder Cancer (21)
2. Brain and CNS Cancer (64)
3. Breast Cancer (56)
4. Colorectal Cancer (56)
5. Esophageal Cancer (25)
6. Gastric Cancer (35)
7. Head and Neck Cancer (41)
8. Kidney Cancer (21)
9. Leukemia (83)
10. Liver Cancer (29)
11. Lung Cancer (166)
12. Lymphoma (61)
13. Melanoma (57)
14. Myeloma (26)
15. Ovarian Cancer (44)
16. Pancreatic Cancer (44)
17. Prostate Cancer (7)
18. Sarcoma (39)
1. Bladder Cancer (8)
2. Breast Cancer (26)
3. Colorectal Cancer (23)
4. Kidney Cancer (11)
5. Liver Cancer (7)
6. Lung Cancer (28)
7. Ovarian Cancer (27)
8. Pancreatic Cancer (6)
9. Prostate Cancer (26
p value:   0.002
A
lo
g2
 m
ed
ia
n-
ce
nt
er
ed
 in
te
ns
ity
lo
g2
 m
ed
ia
n-
ce
nt
er
ed
 in
te
ns
ity
B
C
Normal Tumor Normal Tumor Normal Tumor
  GSE16515   GSE15471   GSE28735
 
 
SL
C1
6A
3
 
 
SL
C1
6A
3
 
 
SL
C1
6A
3
p = 6.96e-07 p = 2.82e-10 p = 7.99e-11
D
147 224
300
67
38
61
62
GSE16515 GSE28735
GSE15471
Term p-Value Fold Enrichment Bonferroni 
collagen fibril 
organization 1.10e-06 19.75112444 8.30e-04 
glycolysis 1.43e-06 13.92784459 0.001077125 
monosaccharide 
catabolic process 2.37e-05 9.219840784 0.017697654 
cellular carbohydrate 
catabolic process 7.63e-05 7.701278772 0.055880152 
E
Low MCT4
High MCT4
0 10 20 30 40 500
20
40
60
80
10
0
p = 0.0414
Time (months)
Pe
rc
en
t S
ur
viv
al
 (%
)
(legend on next page)
2234 Cell Reports 9, 2233–2249, December 24, 2014 ª2014 The Authors
MCT1–MCT4 being preferentially involved in the transport of lac-
tic acid (Halestrap, 2012; Halestrap andMeredith, 2004; Pinheiro
et al., 2012). Export of lactate by MCTs prevents a decrease in
cytosolic pH and inhibition of continued glycolysis (Draoui and
Feron, 2011; Halestrap and Wilson, 2012; Parks et al., 2013).
MCT1 has relatively ubiquitous tissue expression and plays a
role in lactate shuttle in the heart, slow-twitch skeletal muscle,
red blood cells, and the liver. Other MCT proteins demonstrate
more tissue-specific expression, with MCT2 being present in
neurons and MCT3 being limited to retinal pigmented epithelium
and choroid plexus epithelium (Philp et al., 2001). MCT4 is
restricted to ‘‘glycolytic’’ tissues such as rapid-twitch skeletal
muscle and astrocytes (Bergersen et al., 1999; Bergersen,
2007; Bonen, 2000; Halestrap, 2012; Halestrap and Wilson,
2012). Given their central role in controlling intracellular pH and
lactate-based metabolism, MCT1 and MCT4 have been evalu-
ated in various cancers, including cervical (Pinheiro et al.,
2008), colorectal (Pinheiro et al., 2008), breast (Pinheiro et al.,
2010; Whitaker-Menezes et al., 2011), melanoma (Su
et al., 2009), kidney (Gerlinger et al., 2012), and lung (Pinheiro
et al., 2010) cancers. In general, the upregulation of MCT pro-
teins is observed in tumor tissue and supports an apparent
need for lactate shuttling to either fuel tumor growth or enable
survival under stress conditions (Parks et al., 2013).
There is an increasing interest in targeting lactate transporters
in cancer. Much of the emphasis has been on MCT1, which is
generally viewed as playing a pivotal role in lactate influx to facil-
itate mitochondrial metabolism (Doherty et al., 2014; Polanski
et al., 2014; Sonveaux et al., 2012), or CD147, which is a required
scaffolding protein for both MCT1 and MCT4 (Le Floch et al.,
2011; Schneiderhan et al., 2009). Drugs that selectively block
lactate influx through MCT1 have been shown to impact tumor
cell growth and survival (Draoui et al., 2014), although MCT1 in-
hibition can also block efflux of lactate (Doherty et al., 2014).
Functional studies have shown that the inhibition of specific
lactate transporters can result in disparate effects on tumor
cell proliferation and viability depending on the model used,
the nature of the targeted transporter, and the methodology em-
ployed to measure the impact on metabolism (Doherty et al.,
2014; Gerlinger et al., 2012; Le Floch et al., 2011; Lee et al.,
2012; Polanski et al., 2014; Schneiderhan et al., 2009; Sonveaux
et al., 2012).
Here, we evaluated the expression of lactate transporters in
PDA and observed a striking upregulation of the Slc16A3 gene
encoding MCT4. MCT4 expression was heterogeneous in PDA
and associated with glycolytic metabolism and poor prognosis.
This finding was confirmed by immunohistochemical analysis
in a large cohort of pancreatic carcinoma cases, and the prog-
nostic significance was retained in multivariate analysis. MCT4Figure 1. MCT4 Expression Is Elevated in PDA
(A) Gene-expression analyses of SLC16A3 in a panel of cancer cell lines demons
cancer cell types.
(B) Gene-expression analyses of SLC16A3 demonstrated significantly increased
(C) Differential expression analyses demonstrated increased expression of SLC1
(D) Hierarchical clustering of MCT4-correlated genes, and overlap among the th
(E) Top Gene Ontology categories associated with the MCT4 signature and their
See also Figure S1.
Cell Redepletion in ‘‘addicted’’ models resulted in a metabolic crisis
that invoked compensatory mechanisms related to multiple
metabolic pathways and nutrient-scavenging mechanisms. In
spite of these adaptations, MCT4 depletion had a pronounced
impact on cellular viability and tumorigenic growth that was
further augmented by targeting of compensatory processes.
Together, these data underscore the metabolic diversity of
PDA, the key regulatory function of MCT4, and the intersecting
roles of multiple metabolic processes in specifying tumor cell
survival.
RESULTS
Expression of MCT1-4 in Pancreatic Cancer
Initially, the genes encoding the key lactate transporters MCT1–
MCT4were evaluated in PDA. Among these genes, only Scl16A1
(encoding MCT1) was elevated in tumor versus normal speci-
mens (Figure S1). However, there was little overexpression of
Slc16A1 in PDA versus other cancers (Figure S1). In contrast,
the levels of the Slc16A3 transcript encoding MCT4 were high
in PDA and comparable to those in renal clear cell carcinoma,
which is known to express very high levels of MCT4 (Gerlinger
et al., 2012). This was apparent in both cell lines (Figures 1A
and S1) and tumor samples (Figures 1B and S1). In addition,
Slc16A3 expression was considerably higher in tumor speci-
mens than in normal specimens (Figure 1C). To determine the
gene-expression program associated with elevated Slc16A3,
we identified genes with a high positive or negative correlation
to Slc16A3 from each of the data sets (Figure 1D). Genes that
were common to two of the three data sets were employed as
an ‘‘Slc16A3/MCT4 signature.’’ Gene Ontology analysis demon-
strated that high Slc16A3 expression is associated with a gene-
expression program involving collagen fibril organization and
multiple aspects of glycolytic metabolism (Figure 1E). Although
PDA generally has a poor prognosis, we evaluated the associa-
tion of Slc16A3 expression levels with overall survival in the data
set that contained clinical follow-up information. Kaplan-Meier
analysis showed that high Slc16A3 was associated with poor
outcome (Figure 1E). These data suggest that although
Slc16A3 is generally elevated in PDA, it also shows a diversity
of expression that has prognostic and functional significance.
Coordinated MCT4 Expression in Tumor Epithelial and
Stromal Compartments Is Associated with Particularly
Poor Prognosis
To further explore the impact of MCT4 on PDA, we analyzed a
cohort of 223 patients who had undergone surgical resection.
Table S1 shows the descriptive statistics (age, tumor size, histo-
logic grade, lymph-node status, stage, margin status, vitaltrated a statistically significant increase in expression in PDA versus 17 other
expression in pancreatic carcinoma versus eight other malignancies.
6A3 in pancreatic carcinoma versus normal tissue.
ree data sets.
association with disease outcome.
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Figure 2. MCT4 Expression Is Associated
with PDA Prognosis
(A–D) Representative images of immunohisto-
chemical staining show high epithelial-specific
staining (A), high stromal and epithelial staining (B),
high stromal-specific staining (C), and low staining
of MCT4 in PDA (D).
(E) Summary of compartment-specific expression
in all cases.
(F) Kaplan-Meier analysis of epithelial MCT4
expression and overall survival.
(G) Kaplan-Meier analysis of stromal MCT4
expression and overall survival.
(H) Kaplan-Meier analysis of combined high
epithelial and stromal MCT4 expression versus all
other conditions.
(I) Univariate analysis of MCT4 staining in epithelial
and stromal compartments.
(J) Cox multivariate analysis of MCT4 staining in
epithelial and stromal compartments.
See also Figure S2 and Tables S1 and S2.status, and treatment information) for the study patient popula-
tion. Representative images of MCT4 immunohistochemical
staining are depicted in Figures 2A–2D. MCT4 levels were high
(panels A and B) or low (C and D) in the tumor compartment,
and correspondingly high (panels B and C) or low (A and D) in
the stromal compartment. As shown in Figure 2E, 121 cases
had high MCT4 expression in the epithelial compartment, 692236 Cell Reports 9, 2233–2249, December 24, 2014 ª2014 The Authorscases had high MCT4 in the stromal
compartment, and 56 cases displayed
high expression in both compartments.
Only 13 cases had high expression in
the stroma and low expression within
the tumor compartment. Thus, although
all combinations could be found, cases
with high stromal MCT4 were clearly
associated with cases that exhibited
high MCT4 staining within the tumor (Fig-
ure 2E). We evaluated both tumor and
stromal MCT4 for association with sur-
vival. Kaplan-Meier analysis showed that
tumors with high MCT4 expression in
either the epithelial compartment or the
stromal compartment had poor survival
(Figures 2F and 2G). These findings were
not a general feature of MCT expression,
as expression of MCT1 was restricted to
the epithelial compartment and was not
associated with outcome (Figure S2).
There was also no discrete association
of MCT1 and MCT4 status in PDA speci-
mens (Figure S2). Importantly, MCT4-
related outcome data were statistically
significant in univariate (Figure 2I) and
multivariate models that incorporated tu-
mor grade and lymph-node status (Fig-
ure 2J). We also evaluated the combinedexpression of epithelial and stromal MCT4 using Kaplan-Meier
survival curves comparing cases that had strong MCT4 expres-
sion in both compartments versus all other cases (Figure 2H;
Table S2). These data demonstrated that elevated expression
ofMCT4 is associatedwith particularly poor survival and suggest
that elevated levels of MCT4 have a specific impact on the
biology of PDA.
Differential Expression of MCT4 in Pancreatic Cancer
Cell Lines
To characterize the function of MCT4 in PDA, we evaluated
endogenous expression across cell lines. These analyses
showed that the majority of PDA cell lines harbor high levels of
MCT4, presumably indicating aggressive disease (Figure 3A).
Consistent with this concept, cell lines that exhibit a ‘‘mesen-
chymal phenotype’’ and are vimentin positive, such as PL45
and Panc1, had higher expression of MCT4 than the ‘‘epithelial
phenotype’’ Capan-2 line (Figure 3B). The expression of LDHA,
which catalyzes the production of lactate from pyruvate, was
largely elevated in pancreatic models, but did not correlate
tightly with the status of MCT4 protein (Figure 3A). The basal pro-
tein expression was related to the relative levels of the MCT4
transcript, and, interestingly, in pancreatic cancer models,
MCT4 was only modestly responsive to hypoxia (Figure S3).
Since mutant KRAS has been invoked as a critical mediator of
pancreatic cancer metabolism, we evaluated the association of
KRAS mutation with MCT4 expression. Interestingly, MCT4
levels were not simply associated with KRAS mutation status,
as PL5 harboring wild-type KRAS expressed higher levels of
MCT4 than the mutant KRAS cell line Capan-2 (Figure 3C).
Recognizing that there are likely multiple means by which
KRAS signaling can be induced in lines with wild-type protein,
we employed MEK inhibitors to define the importance of this
key downstream pathway (Figure 3D). MEK inhibition resulted
in the attenuation of MCT4 expression in all cell lines evaluated,
with the exception of Capan-2, which showed low levels of
endogenous MCT4, indicating that deregulated KRAS/MEK
signaling is required for a high level of MCT4 expression. MEK
suppression had a relatively weak effect on the transcript level
of MCT4 (not shown); however, the use of the proteasome inhib-
itor could largely blunt the attenuation of protein levels with MEK
inhibition (Figure S3). These data were also recapitulated when
KRAS-specific RNAi was used (Figure 3E).
To determine whether MCT4 status was associated with a
metabolic preference in culture, we monitored glycolytic meta-
bolism by assessing the extracellular acidification rate (ECAR),
which is a surrogate measure for lactate secretion as an end
product of glycolysis. As shown in Figure 3F, PL45 and MIA
PaCa-2, which express high levels of MCT4, exhibited substan-
tial glycolytic activity. Interestingly, in these cells, the glycolytic
function appeared to operate at close to maximum capacity,
as indicated by the moderate effects of oligomycin. In contrast,
Capan-2 cells did not substantively engage in glycolysis. Corre-
spondingly, PL45 and MIA PaCa-2 cells were more sensitive to
acute glucose withdrawal than Capan-2 cells (Figure 3G). These
data indicate that MCT4 expression is a potent marker of glyco-
lytic activity.
Inhibition of MCT4 Alters PDA Metabolism
In order to evaluate the functional significance of MCT4 in PDA,
we performed acute knockdown across cell lines. The multiple
siRNAs that were used produced consistent results in targeting
MCT4, with a uniform impact on distal biological processes
(Figure S3). The loss of membrane-associated MCT4 protein
(as revealed by immunofluorescence) and loss of total protein
(as revealed by immunoblot analysis) was demonstratedCell Refollowing RNAi-mediated knockdown (Figures 3H and 3I). Deple-
tion of MCT4 did not affect the mesenchymal nature of these
cells (as indicated by the continued expression of vimentin).
MCT4 knockdown resulted in enhanced expression of MCT1,
whereas CD147, which serves as a dimeric partner for both
MCT1 and MCT4, was only modestly affected. The effect of
MCT4 on MCT1 expression was not transcriptional (data not
shown), but resulted in increased MCT1 localization at the
plasma membrane (Figure S3). These findings are consistent
with the established competition between MCT1 and MCT4 for
CD147 binding and membrane trafficking (Halestrap, 2012;
Kirk et al., 2000). Analysis of glycolysis under this condition
demonstrated a significant suppression in both PL45 and MIA
PaCa-2 cell lines, but almost no effect on Capan-2 cells (Figures
3J–3L). These findings suggest that endogenous high-MCT4
status delineates a metabolic subtype in which high levels of
continued glycolytic activity are dependent on MCT4.
To directly evaluate the impact of MCT4 depletion on meta-
bolism, we measured the consumption of glucose and subse-
quent secretion of lactate into the media (Figure 4A). These
data demonstrated thatMCT4 knockdown resulted in a substan-
tial attenuation of lactate efflux, but glucose uptake persisted.
Interestingly, the overexpression of MCT4 in Capan-2 cells re-
sulted in increased lactate efflux, indicating that MCT4 is suffi-
cient to alter lactate transport (Figure S3). We used isotope
tracers (13C-glucose) to test whether MCT4 silencing altered
the synthesis of lactate from glucose. These data showed that
MCT4 knockdown significant impeded the production of new
lactate (M+3) from glucose (Figure 4B). To directly measure total
intracellular lactate, we employed mass spectrometry (Cheng
et al., 2011; Harrison et al., 2012). MCT4 silencing resulted in
enhanced lactate retention in MIA PaCa-2 and PL45 cells (Fig-
ure 4C), whereas no change was observed in Capan-2 cells
(not shown). These data indicate that failure to export lactate
leads to an accumulation of intracellular lactate and a corre-
sponding decrease in synthetic rates.
We then used isotope tracers (13C-glucose) to test whether
MCT4 silencing altered the labeling of other glucose-dependent
metabolic pathways. Analysis ofmetabolites related to the tricar-
boxylic acid (TCA) cycle indicated enhanced glucose-dependent
labeling (e.g., citrate M+2, aspartate M+2) in MCT4-depleted
cells, suggesting a compensatory increase in mitochondrial
function (Figure 4D). Consistent with these data, there was an in-
crease in oxidative phosphorylation as measured by the oxygen
consumption rate (OCR) with MCT4 knockdown (Figure 4E). One
possible source for the additional mitochondrial utilization of
glucose-derived carbon is pyruvate carboxylation, which con-
verts pyruvate to oxaloacetate. However, metabolite-labeling
patterns that are most indicative of this process (e.g., malate
M+3 and citrate M+5) were significantly attenuated via knock-
down of MCT4 (Figure 4F). We further evaluated pyruvate
carboxylase activity by selectively labeling glucose carbons 3
and 4, and monitoring specific downstream intermediates of py-
ruvate carboxylation (Figure 4G). The results confirmed that
MCT4 knockdown inhibits pyruvate carboxylase-dependent
metabolite labeling, suggesting that additional flux through the
TCA cycle reflects the additional utilization of glucose-derived
acetyl-CoA.ports 9, 2233–2249, December 24, 2014 ª2014 The Authors 2237
LDHA
GAPDH
MCT4
Capan-2
PL45
MIA PaCa-2
Glucose Oligomycin 2-DG
EC
AR
 (m
pH
/m
in)
Time (min)
2
-6
9
17
25
32
40
48
55
63
0 13 25 38 51 63 76 89 101 114 127
71
MCT4
MCT1
CD147
-tubulin
KRAS
MCT4
 Tubulin
PL5PL45 MIA PaCa-2 Capan2
AZD6244
pERK
ERK
MCT4
 Tubulin
- + - + - + - +
R
el
at
iv
e 
ce
ll 
vi
ab
ilit
y 
(%
) Ctrl
No Glc
MCT4
 Tubulin
PL45 MIA PaCa-2
siKRAS +- +-
KRAS
Ca
pa
n-
2
PL
45
PA
N
C-
1
DAPI Vimentin MCT4 Merge
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
DAPI Vimentin MCT4 Merge
PL
45
Ct
rl
PL
45
 
si
M
CT
4
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
A B
C D E
GF
H I
J K L
(legend on next page)
2238 Cell Reports 9, 2233–2249, December 24, 2014 ª2014 The Authors
Since both glucose and glutamine can be utilized in the TCA
cycle, we also evaluated the metabolism of glutamine. Metabo-
lite analysis in the media demonstrated enhanced secretion of
glutamate (Figure 4H). Culturing cells with [U-13C] glutamine
showed enhanced labeling of TCA cycle intermediates in a
pattern indicative of modestly increased contribution of gluta-
mine to anaplerotic pathways, as would be expected in the
setting of suppressed pyruvate carboxylation (Cheng et al.,
2011; Figure 4I). These data suggest that loss of MCT4 leads
to a metabolic crisis, in response to which compensatory mech-
anisms are rapidly engaged to make up for deficits in glycolysis.
Consistent with these facets of metabolic reprogramming, we
observed a significant increase in mitochondrial mass (Figures
5A and 5B) and an increase in reactive oxygen species (ROS)
with MCT4 knockdown that could be reversed by pretreatment
with antioxidant N-acetylcysteine (NAC; Figure 5C). NAC
blocked the HIF1a upregulation observed upon MCT4 knock-
down (Figure S4), as previously described (Chandel et al., 1998).
Upregulation of Alternate Metabolic Processes with
MCT4 Depletion
In addition to standard pathways for energy production and the
genesis of biomolecules, PDA is known to engage in macropi-
nocytosis and autophagy as means of surviving under limited-
nutrient conditions (Commisso et al., 2013; Yang and Kimmel-
man, 2011; Yang et al., 2011). The uptake of fluorescently
labeled dextran is the principle means of quantifying macropino-
cytosis. As shown in Figure 5D, MCT4 knockdown cells showed
a significant increase in labeled dextran compared with controls.
This could be clearly observed on a per-cell basis in confocal z
stacks of the cells (Figure S4). Quantitation of particles on a
per-cell basis demonstrated a significant increase in macropino-
cytosis (Figure 5E). Autophagywas analyzed using LC3 lipidation
and the protein levels of p62 (Figure 5F). The results demon-
strated a significant increase in lipidated LC3 and corresponding
decreased levels of p62, consistent with increased autophagy
with MCT4 depletion, and the use of chloroquine confirmed
that MCT4 depletion enhanced autophagic flux (Figure S4). In-
duction of autophagy upon MCT4 knockdown was associated
with induction of REDD1, which couples ROS-mediated HIF1a
activation to the suppression of mTOR1 signaling and subse-
quent inhibition of ULK1 phosphorylation (Figure S4). Together,
these findings indicate that multiple processes are engaged to
compensate for the acute loss of MCT4 in cells that expressFigure 3. MCT4 Expression in Pancreatic Cancer Cell Lines Denotes G
(A) Levels of MCT4 and LDHA were determined across a panel of pancreatic can
(B) The indicated pancreatic cancer cell lines were costained for vimentin and M
(C) The levels of MCT4 were determined in cell lines with varying KRAS mutation
(D) The indicated PDA cell lines were treated with the MEK inhibitor AZD6244 an
(E) The effect of KRAS knockdown on MCT4 protein level was determined by we
(F) The indicated PDA cell lines were subjected to a glycolysis stress test with gluco
with an XF analyzer.
(G) The indicated PDA cell lines were cultured in the absence of glucose and sur
(H and I) The indicated cell populations were transfected with control or MCT4-s
shown.
(J–L) PL45, Capan-2, and MIA PaCa-2 cells transfected with control or MCT4-spe
and 2-DG delivered at the indicated time. ECAR was measured with an XF analy
See also Figure S3.
Cell Rehigh levels of the protein, and suggest that MCT4 depletion
has a significant impact on cellular fitness.
In order to probe the impact of MCT4 depletion on these
disparate adaptive processes, we performed gene-expression
profiling. As shown in Figure S4, efficient knockdown was per-
formed in all cell populations with significant alterations in gene
expression specific to models with high endogenous levels of
MCT4. Selective glycolytic enzymes were downregulated upon
knockdown in PL45 and Mia PaCa-2, whereas no change was
observed in Capan-2 cells (Figure S4). Correspondingly, Gene
Ontology analyses showed that the predominant upregulated
genes were significantly associated with blood vessel bio-
genesis (recognized adaptation to hypoxia) and apoptosis
(Figure S4).
MCT4 Depletion Compromises Pancreatic Cancer Cell
Survival and Limits Tumorigenic Growth
Morphological analysis of cells with MCT4 knockdown demon-
strated an attenuation of cell number and the presence of cells
with a refractile appearance (Figure 6A). Flow-cytometric anal-
ysis revealed suppression of cell-cycle progression (as deter-
mined by bromodeoxyuridine incorporation) and apoptotic
cell death (as determined by sub-2N DNA content and Cleaved
Caspase-3 immunofluorescence staining) as a consequence of
MCT4 knockdown in models that expressed high levels of
MCT4 (Figures 6B and 6C). Lastly, analysis of overall viability
demonstrated a significant loss of viability that was largely
restricted to cell lines with high endogenous expression of
MCT4 (Figure 6D) and was not observed with the knockdown
of MCT1 (Figure S5). Furthermore, the depletion of CD147
had only a modest effect on cell viability across all models (Fig-
ure S5). These data indicate that tumor cells that exhibit high
levels of MCT4 are ‘‘addicted’’ to this metabolic state, and
despite the compensatory mechanisms that are engaged,
viability is compromised. In long-term analysis, cells with
MCT4 knockdown failed to proliferate, and the resultant cells,
which ultimately populated the culture, uniformly regained the
expression of MCT4, indicating that there is a key selection
for this protein (Figure S5).
To delineate the processes associated with the induction of
cell death, we investigated different means of mitigating the
proximal effects of MCT4 depletion. First, since lactate synthesis
is largely dependent on LDHA, we utilized LDHA knockdown to
limit lactate accumulation. As shown in Figure 6E, isolatedlycolytic Metabolism
cer cell lines. GAPDH served as the control for loading.
CT4 expression. Representative images of the staining are shown.
status.
d the indicated proteins were detected by immunoblotting.
stern blot in KRAS-specific, RNAi-transfected Pl45 and MIA PaCa-2 cells.
se, oligomycin, and 2-DGdelivered at the indicated time. ECARwasmeasured
vival was measured by CellTiter-Glo assay (****p < 0.001).
pecific RNAi; immunoblotting (H) and representative fluorescent images (I) are
cific RNAi were subjected to a glycolysis stress test with glucose, oligomycin,
zer.
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Figure 4. MCT4 Knockdown Leads to Reprogramming of Glucose Metabolism
(A) Medium for nutrient quantitation (DMEMwith 10% dialyzed FBS, 20 mM glucose, 4 mM glutamine) was changed at 48 hr posttransfection, and then 0.7 ml of
medium was obtained 24 hr later from the indicated cell lines with control or MCT4 knockdown. Concentrations of glucose, lactate, glutamine, and glutamate
were determined using an electrochemical analyzer (BioProfile Basic-4 analyzer; NOVA) (**p < 0.01). Medium obtained from the indicated cell lines with control or
MCT4 knockdown was utilized for the quantitation of glucose consumption and lactate secretion (**p < 0.01).
(B) 13C-glucose labeling and liquid chromatography/mass spectrometry (LC/MS) detection were utilized to measure metabolic flux. Analysis of lactate reveals
diminished label incorporation with knockdown of MCT4 (*p < 0.05).
(legend continued on next page)
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LDHA knockdown had a modest effect on cell viability, but could
partially rescue the toxicity observed with MCT4 knockdown.
Methylpyruvate, a membrane-permeable form of pyruvate,
also partially rescued the cell death with MCT4 depletion (Fig-
ure 6F). These data suggest that loss of cell viability with MCT4
knockdown is a reflection of metabolic defects associated with
lactate accumulation. Interestingly, glucose deprivation neither
antagonized nor was additive for MCT4 knockdown, suggesting
that the distal mechanisms of those metabolic crises are over-
lapping (Figure S6). The antioxidant agent NAC inhibited MCT4
knockdown-induced ROS accumulation and rescued cell via-
bility (Figure 6G).
To determine whether the adaptive biological responses of
increased mitochondrial metabolism, macropinocytosis, and
autophagy were relevant for transient survival with MCT4 deple-
tion, we carried out pharmaceutical challenges relevant to each
process (Figures 6H–6J and S6). As shown in Figure 6H, MCT4
knockdown sensitized the cells to further cell killing in combina-
tion with themitochondrial complex 1 inhibitor phenformin. In or-
der to focus specifically on drug effects beyond the impact of
MCT4 depletion, we normalized the data to the untreated con-
trols. Consistent with the effects of phenformin, low doses of
the complex 1 inhibitor rotenone had a moderate but significant
effect on survival that was specific to MCT4-depleted cells (Fig-
ure S6). More profound effects were observed with the inhibitors
of macropinocytosis (EIPA) and autophagy (chloroquine) (Fig-
ures 6I and 6J). Sensitivity to EIPA was specific to cell lines
with high levels of endogenous MCT4 (e.g., PL45 and MIA
PaCa-2). In contrast, treatment with chloroquine resulted in
impaired cell survival in all models. Lastly, to assess the impact
ofMCT1 inhibition, we treated cells with AR-C155858, which had
limited activity as a single agent but cooperated with MCT4
knockdown (Figure S6).
To determine the potential effects of MCT4 on the tumorigenic
growth of pancreatic cancer cells, we employed stable short
hairpin RNA (shRNA)-mediated knockdown. Lentiviral infection
of shRNA limited the expression of MCT4 in pancreatic cancer
cell lines (Figures 7A and 7B). Although cells could survive with
the residual expression of MCT4, these cell populations grew
slowly relative to controls (Figure 7C). To evaluate the effect of
MCT4 on tumorigenic growth, we injected parental MIA PaCa-
2 and PL45 cells expressing high levels of MCT4 subcutaneously
into the left flank of NSG mice, and MIA PaCa-2 shMCT4 and
Pl45 shMCT4 cells into the contralateral flank of the same ani-
mals. Mice were sacrificed when they became moribund or tu-(C) LC/MS was used to determine the intracellular levels of lactate in control or M
(D) 13C-glucose labeling and LC/MS detection were utilized to measure metaboli
with the knockdown of MCT4 (*p < 0.05).
(E) Oxidative metabolism was measured by OCR in the presence of control or M
(F) 13C-glucose and LC/MS were utilized to measure metabolic flux. Analysis of sp
activity (*p < 0.05, **p < 0.01, ***p < 0.001).
(G) Selectively labeled 13C-glucose was used to monitor specific pyruvate carbo
pyruvate carboxylase (*p < 0.05).
(H) Medium obtained from the indicated cell lines with control or MCT4 knockdo
efflux (****p < 0.0001).
(I) 13C-glutamine labeling and LC/MS detection were utilized to measure meta
increase in glutamine utilization through the TCA cycle (**p < 0.01, ***p < 0.001).
See also Figure S4.
Cell Remors exceeded 1,000 mm3. In all cases (n = 14 total), the mice
were sacrificed due to the growth of the control MCT4-proficient
tumor. Tumors with MCT4 knockdown were smaller as deter-
mined by wet weight (Figure 7D) and by visual inspection (Fig-
ure 7E). Consistent with the cell culture findings, we observed
that reduced MCT4 levels were associated with a lower prolifer-
ative index (Ki67) and higher apoptotic index (Cleaved Caspase-
3) in the tumor tissues analyzed (Figure S7).
Together, these data indicate that MCT4 plays a critical role in
the tumorigenic features of pancreatic cancer and correlate with
our observations from clinical cases. To determine how MCT4
knockdown influenced tumormetabolism, we carried outmetab-
olomic profiling on matched tumors (Figure 7F). The data re-
vealed that MCT4 depletion had a profound impact on tumor
metabolism (Figure 7G). Ametabolomic analysis of tumor tissues
showed an increase in lactate levels in shMCT4 tumors, con-
sistent with an inability to excrete this metabolite and similar to
previous observations (Schneiderhan et al., 2009). Similarly,
depletion of MCT4 was associated with low intratumoral gluta-
mate, consistent with increased export of glutamate into the
media with MCT4 depletion in cell culture. shMCT4 tumors dis-
played low levels of glutathione, consistent with oxidative stress.
The high levels of asparagine observed in shMCT4 tumors could
be a result of asparagine synthetase activation, which is induced
in response to metabolic stress and may protect against de-
creased intracellular pH (resulting from accumulation of lactate)
by providing a source of ammonia (Balasubramanian et al.,
2013; Gouzy et al., 2014). Levels of hydroxyphenylpyruvate
were increased, possibly indicating that it serves as an energetic
substrate for the mitochondrial respiratory chain as well as an
antioxidant (Cotoia et al., 2014). Thus, MCT4 depletion repro-
grams facets of pancreatic cancer metabolism, leading to a
deficit in tumorigenic behavior.
DISCUSSION
It is increasingly being recognized that tumor cells exhibit unique
metabolic adaptations that influence the biological behavior of
the tumor and have prognostic and therapeutic implications
(Cheong et al., 2012; White, 2013). Indeed, these properties are
collectively now considered an ‘‘emerging hallmark’’ of cancer
(Cheong et al., 2012; Hanahan and Weinberg, 2011). A well-
known example of such an adaptation is the Warburg effect,
in which tumor cells exhibit aerobic glycolysis and develop
adaptive mechanisms that allow them to survive under acidicCT4 knockdown cell lines (**p = 0.02, ****p < 0.0001).
c flux. Analysis of aspartate and malate revealed enhanced label incorporation
CT4 knockdown.
ecific labeled metabolites suggested the suppression of pyruvate carboxylate
xylase activity. The data show that attenuation of MCT4 inhibits flux through
wn was utilized for the quantitation of glutamine consumption and glutamate
bolic flux. Analysis of specific metabolites indicated a statistically significant
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Figure 5. Attenuation of MCT4 Leads to Compensatory Upregulation of Macropinocytosis and Autophagy
(A) Mitochondrial mass was determined by staining with a mitochondrial-specific probe (MitoTracker Red). MitoTracker intensity was measured by flow-cyto-
metric analysis.
(B) Cells were labeled with mitochondrial mCherry. Representative images with two different types of MCT4-specific RNAi are shown. Fluorescence was
quantified by flow-cytometric analysis.
(C) Control and MCT4 knockdown cells were treated with a fluorogenic probe to measure ROS. Mean fluorescence intensity represents ROS production.
(legend continued on next page)
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conditions (Cheong et al., 2012; Gatenby and Gillies, 2004; Kim
andDang, 2006; Le et al., 2012). Production of lactate is the oblig-
atory byproduct of glycolysis under such conditions, and cancer
cells develop several mechanisms that allow them to eliminate
excess lactate and survive (Gatenby and Gillies, 2004; Gladden,
2004; Parks et al., 2013). Here, we interrogated a key modulator
of lactate homeostasis, MCT4, in the context of PDA.
To date, analysis of PDA has failed to yield specific subtypes
that have relevance to treatment of the disease (Tempero
et al., 2013). The Slc16A3 gene is highly expressed in PDA rela-
tive to other cancers, and overexpression is amajor feature in the
transition from normal cells to tumor. The expression of Slc16A3
is associated with a glycolytic program that is tightly correlated
with key enzymes such as hexokinase 2 (HK2), pyruvate kinase
2 (PKM2), and phosphofructo-kinase (PFK). These data suggest
that Slc16A3 is a significant feature of a subtype of pancreatic
cancer that is particularly glycolytic. Interestingly, in other tumor
types, including Myc-driven Burkitt lymphoma, a subset of
breast and lung cancer MCT1 is significantly upregulated and
has been shown to correlate with high levels of glycolysis (Birsoy
et al., 2013; Doherty et al., 2014; Polanski et al., 2014). Surpris-
ingly, Slc16A3was also associated with gene expression related
to collagen organization. Although the basis for this association
is currently under investigation, it suggests an intimate coupling
between metabolism and the tumor microenvironment. In gen-
eral, more aggressive pancreatic cancer cell lines that have
progressed through the epithelial to mesenchymal transition ex-
press higher levels of MCT4 protein and harbor a glycolytic
metabolism. Similarly, clinical PDA cases expressing high levels
of MCT4 in the tumor and associated stromal compartments
have the worst outcome (median survival: 13.8 months). The
regulation and function of stromal MCT4 in this context remain
poorly understood. In PDA, the majority of cases that express
stromal MCT4 also express high levels of MCT4 in the tumor,
suggesting that these events are coupled. Consistent with this
point, stromal MCT4 expression is not observed in normal
pancreatic tissue or pancreatitis. These data indicate that
MCT4 defines a ‘‘metabolic subtype’’ of PDA with particularly
poor prognosis.
Targeting the unique features of tumor metabolism is increas-
ingly being considered a viable therapeutic strategy. The strong
reliance of cancer cells on glucose metabolism yields significant
production of lactate. In the absence of mechanisms to export
lactate, metabolic feedback mechanisms related to both in-
tracellular pH and the accumulation of intracellular lactate can
compromise subsequent production of ATP (Parks et al.,
2013). Consistently, high levels of MCT4 correlated with a prefer-
ence for glycolytic metabolism, and depletion ofMCT4 had a sig-
nificant impact on ECAR. These findings indicate that MCT4 is
required for efficient glycolytic metabolism in pancreatic cancer
models. Since metabolic networks are complex, with multiple
existing compensatory mechanisms, we utilized isotope tracing
to determine how MCT4 status affects the utilization of glucose(D) Cells with control or MCT4 knockdownwere exposed to rhodamine-labeled de
(E) Dextran particles were quantified from confocal images using ImageJ softwa
(F) Cell lysates were prepared from control or MCT4 knockdown cells as indicat
See also Figure S5.
Cell Reand glutamine. Consistent with the ECAR results, the evidence
suggested that MCT4-depleted cells rebalanced the fate of
glucose with a shift toward oxidative metabolism. One potential
pathway to supply oxidative metabolism is through the action
of pyruvate carboxylase, and inherited deficiency of pyruvate
carboxylase causes lactic acidosis due to increased pyruvate
pools (Jeoung et al., 2014). Interestingly, although cancer cells
can utilize pyruvate carboxylase to survive under conditions of
glutamine deprivation (Cheng et al., 2011), instead of increasing
with MCT4 knockdown, this activity is suppressed, suggesting
that pyruvate is being utilized through acetyl-CoA rather than
oxaloacetate. Importantly, these data indicate that under condi-
tions of interrupted lactate export by depletion of MCT4, there is
a compensatory enhancement of mitochondrial metabolism. In
addition to conventional metabolic pathways, macropinocytosis
and autophagy have emerged as important sources of metabo-
lites under stress conditions. Interestingly, with the depletion
of MCT4, both of these processes were further augmented.
This is particularly striking considering that pancreatic cancers
models already exhibit ‘‘activated’’ levels of these processes
(Commisso et al., 2013; Yang and Kimmelman, 2011; Yang
et al., 2011). Importantly, these composite data underscore the
overall importance of targeting lactate efflux, given the multiple
downstream effects on tumor cell metabolism. The idea of tar-
geting tumor metabolism therapeutically has been extensively
considered. In general, therapeutic strategies targeting tumor
metabolism involve inhibiting a particular nutrient source or
metabolic pathway in ‘‘addicted tumors.’’ For example, multiple
trials are assessing the impact of Lonidamine and TLN232, which
target hexokinase and pyruvate kinase, respectively (Tennant
et al., 2010). However, given the diverse energy and nutrient
sources available to KRAS-driven tumors, these approaches
may be challenging (White, 2013). Based on the significant
effects on multiple aspects of metabolism, we reasoned that
MCT4 depletion targeting ‘‘waste removal’’ could represent an
important therapeutic target. Although no specific drugs against
MCT4 are currently available, acute and stable knockdown had a
profound effect on cell survival, inducing apoptotic cell death.
This effect was particularly significant for subsets of pancreatic
cancer cells that exhibit high levels of the protein and presum-
ably are ‘‘addicted’’ to the presence of MCT4. The data pre-
sented here provide a rationale for employing selective blockade
of MCT4 in a subset of PDA with a particularly poor prognosis.
Interestingly, sensitivity to monocarboxylate lactate transporters
seems to be an emerging theme, as disruption of another lactate
transporter, MCT1, in glycolytic tumors that preferentially ex-
press this transporter was shown to lead to an accumulation of
intracellular lactate and tumor cell death (Doherty et al., 2014;
Polanski et al., 2014). Importantly, in contrast to the wide expres-
sion of MCT1, MCT4 expression is relatively restricted and thus
may provide a potent therapeutic index. However, MCT4 deple-
tion did serve to further sensitize PDA tumor cells to MCT1
inhibitors, suggesting that the ‘‘dual’’ blockade of tumor-inducedxtran. Uptake of themacromolecules was determined by confocal microscopy.
re (*p < 0.05).
ed and immunoblotted for p62 and lipidated LC3.
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lactate transporters could be a viable strategy in specific tumor
types. MCT4 depletion was also synergistic with inhibitors of
autophagy and macropinocytosis, suggesting that synchronous
targeting of multiple compensatory pathways could enhance
therapeutic responses.
In this work, we performed a detailed analysis of lactate trans-
porter function and the resultant impact on pancreatic cancer
biology. Our data demonstrate that there is substantial diversity
in metabolic preference that has not been previously appreci-
ated. This finding was unexpected, given that KRAS mutation
occurs in 95% of PDA and is viewed as being the key driver
of metabolic preference, resulting in a relatively monolithic
view of the disease and its metabolism. MCT4 status is both
associated with and required for glycolytic metabolism with
lactate as an endpoint. MCT4 expression is associated with
poor prognosis in a cohort of PDA specimens, suggesting that
MCT4 is a key marker and determinant of the metabolic state
associated with aggressive cancer biology. The data obtained
from clinical specimens suggested that only a subset of PDA is
addicted/dependent on MCT4 function, and this was confirmed
in multiple functional studies. In addicted models, MCT4 deple-
tion has dramatic effects onmultiple facets of metabolism. There
is an increased utilization of oxidative phosphorylation, with both
glucose and glutamine serving as energy sources. Although this
would generally be viewed as the default compensatory mecha-
nism, surprisingly, pyruvate carboxylation is inhibited by MCT4
depletion, with most glucose-derived carbon ostensibly coming
into the TCA cycle as acetyl-CoA. This compensatory reliance on
mitochondrial-based metabolism is associated with production
of ROS. The increase in ROS leads to the induction of multiple
downstream effector mechanisms, including hypoxia signaling
and autophagy. Surprisingly, these adaptations to suppres-
sion of MCT4 are not sufficient to rescue apoptotic cell death,
although targeting compensatory pathways in concert with
MCT4 knockdown augmented cell death via metabolic crisis.
Importantly, we show that the metabolic dependence on MCT4
is maintained during tumorigenic growth and has a profound ef-
fect on tumor biology. These findings illustrate the metabolic di-
versity of PDA as described by the presence of MCT4, delineate
pathways through which MCT4 supports cancer growth/viability
by influencing multiple important metabolic features of disease,
and demonstrate that MCT4-high PDA can be rationally targeted
based on metabolic addictions.Figure 6. MCT4 Is Required for the Viability of PDA Cells with High En
(A) Representative phase-contrast images of PL45 cells with control or MCT4 kn
(B) Flow-cytometry analysis of bromodeoxyuridine incorporation (left panel) and
(C) Immunofluorescence staining for Cleaved Caspase-3 from PL45 cells with co
(D) Analysis of cell viability by Cell-Titer Glow analysis from the indicated cells tran
and UBB RNAi (positive control).
(E) Cells were transfected with MCT4-specific or LDHA-specific RNAi. Cell viabil
(F) Cells were transfected with MCT4-specific RNAi and cotreated with 4 mM o
analysis.
(G) Cells were transfected with MCT4-specific RNAi and cotreated with 2 mM of
(H) Cells transfected with control orMCT4-specific RNAi were exposed to phenfor
Glow analysis.
(I and J) Cells transfected with control or MCT4-specific RNAi were exposed to
normalized impact of the agents on survival is plotted (*p < 0.05, **p < 0.01, ***p
See also Figure S6.
Cell ReEXPERIMENTAL PROCEDURES
Cell Culture
The human pancreatic adenocarcinoma lines PL45, Capan-2, MIA PaCa-2,
18128, PANC-1, and Panc 04.03 were cultured under 5% CO2 at 37
C in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma) supplemented with
10% fetal bovine serum (FBS), penicillin/streptomycin, and 4 mM L-glutamine.
Immunofluorescence and Microscope Imaging
Cells were seeded onto glass coverslips in six-well plates. Staining was per-
formed after cells reached 70%–90% confluence. Cells were washed with
PBS, fixed in 3.7% formaldehyde for 15min at room temperature, permeabilized
in 100% methanol for 5 min, and then washed with PBS again. The cells were
thenblocked in IF buffer (PBS, 0.5%NP40, and5%BSA) for 10min at room tem-
perature. Primary antibodies, diluted in IFbuffer,were incubatedwith the cells for
1 hr at room temperature in a humidified chamber. The cells were washed with
PBS and then incubated in fluorescent-conjugated secondary antibodies diluted
in IF buffer for 30 min at room temperature in a humidified chamber. The cells
were again washed three times in PBS, costained with DAPI (in PBS), and
mounted onto slides usingmounting reagent (ProLongGold Antifade; Life Tech-
nologies). The followingantibodieswereused: anti-vimentin (mousemonoclonal;
Abcam), anti-MCT4 (sc-50329, rabbit polyclonal; Santa Cruz Biotechnology),
anti-cleaved caspase3 (D175, rabbit polyclonal; Cell Signaling Technology),
anti-rabbit Alexa Fluor 488 conjugated immunoglobulin G (Life Technologies),
and anti-rabbit Alexa Fluor 546 conjugated immunoglobulin G (Life Technolo-
gies). Images were captured using a Zeiss fluorescent microscope (Zeiss).
Measurement of ECAR and OCR
Cells were seeded into an XF assay microplate (Seahorse Bioscience) 1 day
before the day of assay. The assay cartridge was hydrated overnight at
37C in a CO2-free incubator. On the day of assay, the growth medium was
changed with assay medium (DMEM with 1.85 g/L NaCl, 3 mg/L phenol red,
2 mM L-glutamine). Glucose, oligomycin, and 2-DG for ECAR, and oligomy-
cine, FCCP, and rotenone for OCR were sequentially injected into each well
in accordance with the manufacturer’s standard protocol. The resultant alter-
ations in pH andmitochondrial respiration were measured by the sensor probe
on an XF24 extracellular flux analyzer (Seahorse Bioscience). Results were
normalized to the protein content of each well.
Nutrient Utilization and Secretion
Cells were seeded in six-well plates and 1 ml of medium was collected from
each well in triplicate. Concentrations of glucose, lactate, glutamine, and
glutamate were determined using an automated electrochemical analyzer
(BioProfile Basic-4 Analyzer; NOVA). Metabolic concentrations were normal-
ized by protein content using the BCA Protein Assay (Bio-Rad).
Microarray Analysis
Cells were transfected with either control or MCT4-selective RNAi. Cells were
harvested and total RNA was harvested using standard methods. RNA wasdogenous Levels
ockdown.
sub-2N DNA content (right panel).
ntrol or two different MCT4 knockdowns. Representative images are shown.
sfected with TMEMRNAi (negative control), two different types of MCT4 RNAi,
ity was determined by Cell-Titer Glow analysis.
f methyl pyruvate for 48 hr. Cell viability was determined by Cell-Titer Glow
NAC for 48 hr. Cell viability was determined by Cell-Titer Glow analysis.
min, inhibitingmitochondrial function. Cell viability was determined byCell-Titer
agents that inhibit macropinocytosis (EIPA) or autophagy (chloroquine). The
< 0.001, ****p < 0.0001).
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hybridized on Agilent gene array platforms and differential expression of
robust multiarray average (RMA) normalized data is provided.
Metabolic Tracing Using 13C Stable Isotopes
For analysis of intracellular metabolites by gas chromatography/mass spec-
trometry, 80%–90% confluent cells in 60 mm dishes were washed twice
with PBS, incubated in medium containing 13C isotopically enriched nutrient
([U-13C6] D-glucose, [U-13C5] L-glutamine, [3,4-13C2] D-glucose; Cambridge
Isotope Laboratories), and cultured for 7 hr. Unless otherwise indicated, cells
for metabolic experiments were used 72 hr after control and siMCT4 RNA
transfection. Isotope-labeled cells were washed twice with cold PBS and
lysed with three freeze-thaw cycles in 50% ice-cold methanol and 50%water.
The lysates were centrifuged to remove precipitated protein, a standard
(50 nmol of sodium 2-oxobutyrate) was added, and the samples were evapo-
rated and derivatized by trimethylsilylation (Tri-Sil HTP reagent; Thermo Scien-
tific). Three microliters of the derivatized material was injected into an Agilent
6970 gas chromatograph equipped with a fused silica capillary GC column
(30 m long, 0.25 mm in diameter) and networked to an Agilent 5973 mass
selective detector. The retention times of all of the metabolites were validated
using pure standards. The abundance of the following ions was monitored:
m/z 465-471 for citrate, m/z 334-338 for aspartate, m/z 335-339 for malate,
and m/z 219-222 for lactate. The measured distribution of mass isotopomers
was corrected mathematically for natural abundance of 13C and represented
as a percentage of the total pool. To measure the intracellular lactate pool,
an isotopic standard of lactate was used as described previously (Harrison
et al., 2012).
Tumor Microarray Construction and Population Study
Cases for the study were obtained from the surgical pathology files at Thomas
Jefferson University with Institutional Review Board approval. All animal
studies were performed in accordance with the IACUC guidelines of UT South-
western. The tissue microarray (TMA) contained tumor samples derived from
223 largely consecutive patients with PDA who had been treated at Thomas
Jefferson University Hospitals between the years 2002 and 2010. Prior to
TMA construction, hematoxylin and eosin (H&E) tumor sections from each
case were reviewed and representative areas of PDA were selected. Each
case was represented in the TMA by two cores (6 mmdiameter) and deposited
into a recipient paraffin block with the use of a TMA workstation (TMA builder,
Veridiam). Tissue sections (4 mm) were used for immunohistochemistry and an
H&E-stained section from each TMA block was reviewed to confirm the pres-
ence of morphologically representative areas of the original tissues. Clinical
and treatment information was extracted by chart review.
Immunohistochemistry
Immunohistochemistry was performed as previously described (Witkiewicz
et al., 2012). In brief, MCT1 and MCT4 expression levels were assessed
using a standard avidin-biotin immunoperoxidase method with a rabbit
polyclonal anti-MCT1 (developed and characterized by Dr. Nancy Philp
[Gallagher et al., 2007]; 1:250) and MCT4 antibodies (developed and char-
acterized by Dr. Nancy Philp [Gallagher et al., 2007]; 1:250). TMA sections
were deparaffinized and rehydrated through graded alcohols. Antigen
retrieval was performed in 10 nM citrate buffer (pH 6.0) for 10 min in a pres-
sure cooker. Sections were cooled to room temperature, rinsed in PBS,
blocked with 3% (v/v) H2O2 for 15 min, and then blocked for endogenous
biotin using the Dako Cytomation Biotin Blocking System (Dako). Slides
were then incubated for 1 hr with 10% goat serum and incubated withFigure 7. MCT4 Fuels the Growth of PDA Tumors
(A and B) shRNA-mediated knockdown of MCT4 was confirmed in the indicated
(C) shRNA-mediated knockdown of MCT4 resulted in attenuated proliferative ca
(D and E) Equal amounts of control and MCT4 knockdown cells were injected
1,500 mm3 or the mice became moribund. Depletion of MCT4 was confirmed
tumors are shown.
(F and G) Metabolomic profiling of xenograft tumors indicates an alteration in met
of selected metabolites from the tumors analyzed is shown in arbitrary units.
See also Figure S7.
Cell Reprimary antibody overnight at 4C. Antibody binding was detected using
a biotinylated secondary antibody (Vector Labs) followed by streptavidin
horseradish peroxidase (Dako). Immunoreactivity was detected using 3,30
diaminobenzidine.
Statistical Analysis
Data analyses were conducted in GraphPad Prism software. Stromal MCT4
expression in the TMAs was scored as 0 (none), 1 (weak), or 2 (strong). Epithe-
lial MCT4 and MCT1 were scored as 0 (none), 1–4 (weak), or 6–9 (strong). Sur-
vival curves were computed by expression strata using the Kaplan-Meier
method, and differences between overall survival curves was assessed using
the log rank test. Hazard ratios for the biomarkers were computed using Cox
proportional hazards regression, using the biomarker as predictor. For the
statistical analysis of molecular data, the following convention was utilized:
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
For additional details regarding thematerials andmethods used in this work,
see Supplemental Experimental Procedures.
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